rolipram has been researched along with Neuroretinitis in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rolipram treatment from days -1 to 7 after immunization (afferent phase) was not protective, but severity of EAU was reduced to 50% by treatment from days 8 to 16 after immunization or when EAU was induced by adoptive transfer (efferent phase)." | 1.30 | Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. ( Caspi, RR; Chan, CC; Rizzo, LV; Silver, PB; Strassmann, G; Wiggert, B; Xu, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, H | 1 |
| Strassmann, G | 1 |
| Chan, CC | 1 |
| Rizzo, LV | 1 |
| Silver, PB | 1 |
| Wiggert, B | 1 |
| Caspi, RR | 1 |
1 other study available for rolipram and Neuroretinitis
| Article | Year |
|---|---|
Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Topics: Adoptive Transfer; Animals; Autoimmune Diseases; DNA Primers; Dose-Response Relationship, Drug; Eye | 1999 |